Compare Gilead Sciences, Inc. (GILD) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Warner Music Group Corp — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Gilead Sciences, Inc. is far larger — about 12.1× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (2.77%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Warner Music Group Corp for 96 Days on average.
| GILD | WMG | |
|---|---|---|
Market Cap | $182.40B | $15.12B |
Volume | 4,469,821 | 2,966,414 |
Sector | Health | Media |
52-Week High | $155.80 | $34.72 |
52-Week Low | $116.74 | $23.65 |
Typical Hold Time | 111 Days | 96 Days |
Enterprise Value | $205.46B | $19.42B |
Dividend Yield | 2.23% | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Warner Music Group (WMG) trades at $28.91, up 2.66% on the day, with a bullish technical outlook and strong analyst support. Recent earnings have beaten expectations, with Q2 2026 EPS of $0.38 exceeding the $0.3435 forecast. The company's revenue growth is solid, projected to reach $7.3B in 2026, and it maintains a high return on equity of 92.72%. Positive news includes strategic AI partnerships and a renewed licensing deal with NetEase Cloud Music.
The stock presents a compelling opportunity with a consensus price target of $39.50, implying significant upside. However, risks include recent net cash outflows, a high P/E ratio of 23.12, and competitive pressures in the evolving music industry. Investor sentiment is buoyed by institutional buying and AI-driven growth prospects, but execution on cost management and streaming market share remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
